Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas.
Sunita Patel-HettErika J MartinBassem M MohammedSwapnil RakhePengling SunJohn C BarrettMelinda E NolteJanice KuhnDebra D PittmanJohn E MurphyDonald F BrophyPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2019)
These studies show the ex vivo potency of marstacimab in restoring haemostasis in whole blood and plasmas from haemophilia participants and comparability to ex vivo reconstitution with recombination coagulation factors.